Top Markets
Coin of the day
Fusion Antibodies plc Fusion Antibodies plc

Fusion Antibodies plc

FAB
Rang in Aktien #20442
Fusion Antibodies plc, a contract research organization, engages in the... Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies primarily for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. It offers monoclonal antibody discovery and development, antibody sequencing, antibody engineering, antibody humanization and rational affinity maturation platform, recombinant protein expression, and stable cell line development and cGMP scale up services. The company serves pharmaceutical, biotech, and diagnostic companies. It has a collaboration partnership with Celonic AG. Fusion Antibodies plc was incorporated in 2000 and is headquartered in Belfast, the United Kingdom.
Aktienkurs
$0.16328419
Marktkapitalisierung
$204.14K
Veränderung (1 Tag)
4.35%
Veränderung (1 Jahr)
102.45%
Land
GB
Handel Fusion Antibodies plc (FAB)

Kategorie

EPS für Fusion Antibodies plc (FAB)
EPS zum September 2025 TTM: $-0.02
Laut den aktuellen Finanzberichten und dem Aktienkurs von Fusion Antibodies plc beträgt das aktuelle EPS des Unternehmens (TTM) $-0.02. Am Ende des Jahres 2024 betrug das EPS $-0.05 ein Rückgang im Vergleich zu dem EPS von 2023, das $-0.12 betrug.
EPS-Verlauf von Fusion Antibodies plc von 2013 bis 2026
EPS am Ende jedes Jahres
Jahr EPS ändert
2026 (TTM) $-0.02 -3.00%
2025 $-0.02 -54.35%
2024 $-0.05 -58.93%
2023 $-0.12 102.30%
2022 $-0.06 -59.83%
2021 $-0.15 286.73%
2020 $-0.04 -47.38%
2019 $-0.07 22.53%
2018 $-0.06 -994.12%
2017 $0.01 -90.93%
2016 $0.08 -1,393.10%
2015 $-0.01 -31.76%
2014 $-0.01 -73.60%
2013 $-0.03 0.00%
EPS für ähnliche Unternehmen oder Wettbewerber
Unternehmen EPS EPS-Differenz Land
$3.62 -18,771.65%
DK
$15.47 -79,842.27%
US
$43.12 -222,368.04%
US
$9.62 -49,691.75%
BE
$38.32 -197,625.77%
NL